Cipher Pharmaceuticals Investor Relations Material

Cipher Pharmaceuticals Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, and commercializing prescription products for the dermatology market in Canada. The company's commercial products include Epuris, a recombinant formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin for treating impetigo; Actikerall, which is indicated for the treatment of hyperkeratotic actinic keratosis; Vaniqa that reduces the growth of unwanted facial hair in women; BRINAVESS, an antiarrhythmic agent for the conversion of recent onset or well-tolerated atrial fibrillation; and AGGRASTAT, an intravenous anti-platelet drug. It also develops PEP005 (ingenol mebutate) gel that completed Phase III clinical trials for actinic keratosis and keloid scars; and CIP-Liprodex (DFF 450), which is in Phase II clinical trials to treat localized liposarcomas.